An Unexpected Breakthrough What an IVIG Case Report May Teach Us About Long COVID and PVS

This lecture explores a novel and thought-provoking case report describing the successful use of recombinant C1 esterase inhibitor (C1-INH) to prevent severe adverse events associated with subcutaneous immunoglobulin (SCIG) therapy in a patient with primary immunodeficiency (CVID). Immunoglobulin replacement therapy is lifesaving for patients with antibody deficiencies, yet a subset of individuals experience significant infusion-related reactions that limit dosing and compromise treatment efficacy. In this case, the treating physician hypothesized that complement activation—an innate immune pathway—was driving the patient’s neuropathic and inflammatory symptoms. By administering C1-INH prophylactically prior to SCIG, the patient was able to tolerate full therapeutic dosing without recurrence of severe adverse events.

We will examine the immunologic mechanisms underlying complement activation, the regulatory role of C1-INH in controlling classical and lectin pathway signaling, and how innate immune overactivation may contribute to infusion intolerance. The discussion will move beyond the case itself to consider broader implications: Are some IVIG/SCIG adverse events primarily complement-mediated? Could targeted complement modulation represent a precision strategy for managing immunoglobulin intolerance? And what are the practical, mechanistic, and scalability considerations before such an approach could be adopted more widely? This session integrates clinical reasoning with foundational immunology to provide a deeper understanding of infusion-related inflammatory phenomena.

Disclaimer:

This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.

Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

#CVID #PrimaryImmunodeficiency #ImmunoglobulinTherapy #IVIG #SCIG #C1EsteraseInhibitor #ComplementSystem #InnateImmunity #AdaptiveImmunity #Immunology #ClinicalImmunology #ImmuneDysregulation #InfusionReactions #RedManSyndrome #ComplementActivation #Inflammation #Autoimmunity #ImmuneMechanisms #MedicalEducation